Is MIBG a substrate of P-glycoprotein?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 4, 2007, Pages 448-452

  Kiyono, Yasushi ^a   Yamashita, Tomoko ^b   Doi, Hisako ^b   Kuge, Yuji ^b   Katsura, Toshiya ^a   Inui, Ken Ichi ^a   Saji, Hideo ^b  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

131I MIBG; Neuroendocrine tumour; P glycoprotein; Radionuclide therapy; Transporter

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; DAUNORUBICIN; GLYCOPROTEIN P;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; INCUBATION TIME; NEUROENDOCRINE TUMOR; NONHUMAN; PROTEIN EXPRESSION; RADIOACTIVITY; TRANSCYTOSIS;

3-IODOBENZYLGUANIDINE; ANIMALS; CELL LINE; KIDNEY; METABOLIC CLEARANCE RATE; P-GLYCOPROTEIN; PROTEIN BINDING; RADIOPHARMACEUTICALS; SWINE;

EID: 33947224527     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0256-6     Document Type: Article

References (22)

1. Bombardieri E, Seregni E, Villano C, Chiti A, Bajetta E. Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. Q J Nucl Med Mol Imaging 2004;48:150-3.
2. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000;190:432-5.
3. Carty SE, Jensen RT, Norton JA. Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery 1992;112:1024-31; discussion 1031-2.
4. Norton JA, Warren RS, Kelly MG, Zuraek MB, Jensen RT. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 2003;134:1057-3; discussion 1063-5.
5. 131I]iodobenzylguanidine. J Nucl Med 1980;21:349-53.
6. Wafelman AR, Hoefnagel CA, Maes RA, Beijnen JH. Radio-iodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med 1994;21:545-59.
7. 131I-mIBG]. Clin Endocrinol (Oxf) 2001;55:47-60.
8. Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman JM, Leight GS Jr, et al. Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 2003;134:956-62; discussion 962-3.
9. 131I-MIBG therapy. Clin Oncol (R Coll Radiol) 2003;15:193-8.
10. Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman J, Onaitis MW, et al. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer 2004;101:1987-93.
11. Campling BG, Young LC, Baer KA, Lam YM, Deeley RG, Cole SP, et al. Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer. Clin Cancer Res 1997;3:115-22.
12. Chan HS, Haddad G, Thorner PS, DeBoer G, Lin YP, Ondrusek N, et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991;325:1608-14.
13. De Moerloose B, Van de Wiele C, Dhooge C, Philippe J, Speleman F, Benoit Y, et al. Technetium-99m sestamibi imaging in paediatric neuroblastoma and ganglioneuroma and its relation to P-glycoprotein. Eur J Nucl Med 1999;26:396-403.
14. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989;81:116-24.
15. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
16. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003;22:7468-85.
17. 1). J Pharmacol Exp Ther 1992;263:840-5.
18. 1 and LLC-GA5 col300 renal cells. J Pharmacol Exp Ther 2000;293:697-704.
19. Saito H, Yamamoto M, Inui K, Hori R. Transcellular transport of organic cation across monolayers of kidney epithelial cell line LLC-PK. Am J Physiol 1992;262:C59-66.
20. 1: interaction with organic cation transporters in apical and basolateral membranes. J Pharmacol Exp Ther 1996;276:1143-8.
21. 1 cells. J Pharmacol Exp Ther 1998;286:676-80.
22. 1. Drug Metab Pharmacokinet 2005;20:200-5.